{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:49:52Z","timestamp":1791510592925,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      We investigated whether prompt changes in prostate-specific-antigen (PSA) levels within two days after the first cycle of prostate-specific-membrane-antigen radioligand therapy (PSMA-RLT) with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 predicted treatment response and mean survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a retrospective study of 76 metastatic castration resistant prostate cancer (mCRPC) patients, we evaluated pretreatment PSA-values and their relative changes in PSA (dPSA) two days later. We tested for correlations between dPSA with long-term biochemical response (BCR) to treatment, using a priori criteria for relevant PSA decrease (dPSA &lt; -10%), stable PSA (-10%\u2009\u2264\u2009dPSA\u2009\u2264 +\u200910%) and relevant PSA increase (dPSA\u2009&gt;\u200910%), along with evaluation of biochemical therapy outcome according to the Prostate-Cancer-Working-Group (PCWG3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two days after the first [177Lu]Lu-PSMA-617 cycle, 32 (42%) of the patientsshowed PSA decrease, of whom 19 (59%) had experienced a partial response according toPCWG3 criteria. Of the 37 patients with stable PSA, 17 (46%) showed partial response totreatment according to PCWG3 criteria. Among the seven patients with PSA increase, three(43%) showed partial response. Pearson correlation analysis showed statistically significantcorrelations between dPSA on day 2 and relative Nadir for the first two treatment cycles.Patients with PSA decrease or stable PSA compared to those with an increase of PSA two daysafter cycle 1 lived longer on average (399, 405 and 225 days, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Compared to those with increased PSA levels, patients with decreased or stable PSA levels two days after the first [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 RLT cycle were more likely to have favorable biochemical response according to PCWG3 criteria and presented with a longer overall survival.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07772-y","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:12:58Z","timestamp":1769152378000},"page":"3518-3528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prompt PSA changes as a prognostic marker for response to PSMA-radioligand therapy"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-3516","authenticated-orcid":false,"given":"Wolfram A.","family":"Bosbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radi Saiyed","family":"Alsheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"G\u00f6zl\u00fcg\u00f6l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Caobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Mingels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Akhoundova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna C.","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cumming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-4243","authenticated-orcid":false,"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"7772_CR1","first-page":"1","volume-title":"Prostate Cancer","author":"S Giona","year":"2021","unstructured":"Giona S. The Epidemiology of Prostate Cancer. In: Bott SR, Lim Ng K, editors. Prostate Cancer. Frimley Park Hospital, Portsmouth Rd, Frimley, Camberley GU16 7UJ, UK: Exon Publications; 2021. p. 1\u201316."},{"issue":"10","key":"7772_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"key":"7772_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339.","journal-title":"J Cell Biochem"},{"key":"7772_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7772_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-981-13-7295-7_12","volume-title":"Biomarkers Cancer Ther","author":"K Akakura","year":"2019","unstructured":"Akakura K. Biomarkers of Prostate Cancer. In: Shimada H, editor. Biomarkers Cancer Ther. Singapore: Springer Singapore; 2019. p. 125\u201332."},{"key":"7772_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncol"},{"key":"7772_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet J, Sandhu S, Iravani A, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857\u201365.","journal-title":"J Nucl Med."},{"key":"7772_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85\u201390.","journal-title":"J Nucl Med."},{"key":"7772_CR9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.2967\/jnumed.119.240242","volume":"61","author":"A Gafita","year":"2020","unstructured":"Gafita A, Heck MM, Rauscher I, Tauber R, Cala L, Franz C, et al. Early prostate-specific antigen changes and clinical outcome after 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:1476\u201383.","journal-title":"J Nucl Med"},{"key":"7772_CR10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.eururo.2024.08.021","volume":"86","author":"AJ Armstrong","year":"2024","unstructured":"Armstrong AJ, Sartor O, De Bono J, Chi K, Fizazi K, Krause BJ, et al. Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving [177Lu]Lu-PSMA-617 in the phase 3 VISION trial. Eur Urol. 2024;86:552\u201362.","journal-title":"Eur Urol"},{"key":"7772_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14014","volume":"53","author":"L Giovanella","year":"2023","unstructured":"Giovanella L, Garo ML, Cuzzocrea M, Paone G, Herrmann K. Prognostic role of early prostate specific antigen changes after 177Lu-PSMA radioligand therapy of metastasized prostate cancer. Eur J Clin Invest. 2023;53:e14014.","journal-title":"Eur J Clin Invest"},{"key":"7772_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010149","volume":"14","author":"F Kind","year":"2022","unstructured":"Kind F, Fassbender TF, Andrieux G, Boerries M, Meyer PT, Ruf J. Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predictor of biochemical response and overall survival. Cancers (Basel). 2022;14:149.","journal-title":"Cancers (Basel)"},{"key":"7772_CR13","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","volume":"48","author":"R Manafi-Farid","year":"2021","unstructured":"Manafi-Farid R, Harsini S, Saidi B, Ahmadzadehfar H, Herrmann K, Briganti A, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021;48:4028\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7772_CR14","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate- specific antigen working group. J Clin Oncol. 1999;17:3461\u20137.","journal-title":"J Clin Oncol"},{"key":"7772_CR15","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"7772_CR16","unstructured":"scipy.stats.chi2_contingency [Internet]. SciPy v1.14.1 Man. 2024 [cited 2024 Sep 1]. Available from: https:\/\/docs.scipy.org\/doc\/scipy\/reference\/generated\/scipy.stats.chi2_contingency.html"},{"key":"7772_CR17","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New York: NY, USA; 1988.","edition":"2"},{"key":"7772_CR18","unstructured":"scipy.stats.pearsonr [Internet]. SciPy v1.16.2 Man. 2025 [cited 2025 Nov 12]. Available from: https:\/\/docs.scipy.org\/doc\/scipy\/reference\/generated\/scipy.stats.pearsonr.html"},{"key":"7772_CR19","unstructured":"statsmodels.stats.multitest.multipletests [Internet]. statsmodels 0.15.0 (+841). 2025 [cited 2025 Nov 12]. Available from: https:\/\/www.statsmodels.org\/dev\/generated\/statsmodels.stats.multitest.multipletests.html"},{"key":"7772_CR20","unstructured":"KaplanMeierFitter [Internet]. lifelines 0.30.0. 2025 [cited 2025 Nov 12]. Available from: https:\/\/lifelines.readthedocs.io\/en\/latest\/fitters\/univariate\/KaplanMeierFitter.html"},{"key":"7772_CR21","unstructured":"CoxPHFitter [Internet]. lifelines 0.30.0. 2025 [cited 2025 Nov 12]. Available from: https:\/\/lifelines.readthedocs.io\/en\/latest\/fitters\/regression\/CoxPHFitter.html"},{"key":"7772_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2022.7070","volume":"21","author":"D Mehrens","year":"2023","unstructured":"Mehrens D, Kramer KKM, Unterrainer LM, et al. Cost-effectiveness analysis of [177Lu]Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer. J Natl Compr Cancer Netw. 2023;21:43-50.e2.","journal-title":"J Natl Compr Cancer Netw."},{"key":"7772_CR23","doi-asserted-by":"publisher","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","volume":"7","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Gafita A, De Bono JS, et al. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: Analysis of the phase 3 VISION trial. eClinicalMedicine. 2024;7:102862.","journal-title":"eClinicalMedicine."},{"key":"7772_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","volume":"44","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, K\u00fcrpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7772_CR25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","volume":"49","author":"F Khreish","year":"2022","unstructured":"Khreish F, Ghazal Z, Marlowe RJ, et al. 177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49:1075\u201385.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"7772_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","volume":"48","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617: A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"7772_CR27","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07772-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07772-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07772-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:55:56Z","timestamp":1791507356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07772-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7772"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07772-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ali Afshar-Oromieh, Axel Rominger, and Federico Caobelli are editors in this journal. All other authors have no conflicts of interest to report. All contributing authors read and approved the final version of the manuscript. Novartis has conducted a scientific accuracy and intellectual property review. Novartis has not influenced the content of the publication.","order":1,"name":"Ethics","label":"Declarations","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The local ethics committee approved this retrospective study (project ID-2023\u201302053), and all subjects signed a written informed consent form.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}